Evaluating the efficacy and safety of Deoxycholic acid injection (Embella®) in management of superficial lipomas

Espad pharmed0 个研究点目标入组 10 人开始时间: 待定最近更新: 2024年7月22日

适应症

试验速览

暂无简介。

•having at least one lipoma (clinically and sonographically proven) and accessible for diagnostic and therapeutic approaches with at least two vertical axes measurable and with the following conditions:The history of gradual growth, stability in the last 6 months, single and isolated, with an oval to circular shape, without a hard consistency or connection to the underlying tissue, in the areas of the limbs and trunk and away from sensitive vascular-neural structures
•Weight stability and body mass index less than 30 in the last 3 months
•Ability to complete the study and follow instructions
•Informed consent to participate in the study
•Consent not to undergo any other intervention for lipoma during the study period

•Severe medical or psychological conditions that interfere with study results
•History of hypersensitivity to any of the components of the studied product
•Pregnancy and breastfeeding
•History of previous lipoma treatment
•Patients prone to intravascular volume depletion
•Evidence of recent alcohol consumption or drug abuse
•History of bleeding disorders or recent intake (less than 3 weeks) of thrombolytic drugs, anticoagulants, platelet inhibitors, or NSAIDs
•History of hypertrophic scarring
•Infection, inflammation, dermatosis, non-healing wound, cancer or precancerous lesions at the lipoma site

发起方

Espad pharmed